Resources

High–quality evidence assessing single–dose HPV vaccination suggests that implementing a single–dose schedule is scientifically sound, and provides the greatest public health benefit.A single–dose HPV vaccination schedule has the potential to reach more girls and avert a greater number of cervical cancer cases than reaching fewer girls with a two–dose regimen.This brief provides a list of frequently asked questions and answers about the evidence around single–dose HPV vaccination, and the current policy landscape.

As of March 2026, more than 90 countries have adopted a single-dose HPV vaccination schedule. This brief summarizes critical study findings, estimated public health impacts, and current recommendations to assist policymakers with decision-making.

Sub-Saharan Africa has made remarkable progress, yet approximately 490 mothers and more than 7,500 children under five years still die every day.As global health funding decreases, protecting decades of progress and continuing to build toward a healthier future will require tackling persistent bottlenecks, strengthening civil society advocacy, and coordinating leadership across sectors. What is needed now is bold, sustained political will to ensure every mother, newborn, and child survives and thrives.This published MNCH advocacy resource includes a Sub-Saharan Africa overview brief and country-specific briefs for Zambia, Uganda, Ethiopia, and Tanzania. Together, they outline key calls to action policymakers, funders, and advocates to accelerate the progress needed to improve health outcomes for mothers and children.

In this webinar, researchers from Burkina Faso and Mozambique shared learnings on how country-tailored interventions have helped increase the uptake of the malaria vaccine.As part of Gavi’s Malaria Vaccine Learning Agenda, experts presented findings and lessons learned from the rollout of malaria vaccines in Mozambique and Burkina Faso, sharing strategies to increase uptake through routine immunization platforms. This was the first in a quarterly series this year on learnings from malaria vaccine rollout in Africa.The session was co-moderated by Eleonora Genovese, Senior Programme Manager, Vaccine Programmes, Gavi, the Vaccine Alliance, and Saira Nawaz, Project Director, Primary Health Care, PATH. Featured speakers included Dr. Ali Sie, Centre de Recherche en Santé de Nouna (CRSN), Burkina Faso, and Daan Velthausz, Director, Maraxis BV, Mozambique.

Le cancer du col de l'utérus est le deuxième cancer le plus répandu chez les femmes en Éthiopie, avec plus de 8 000 nouveaux cas estimés en 2022. Afin de contribuer à prévenir de nouveaux cas, l'Éthiopie a introduit le vaccin contre le papillomavirus humain (HPV) en 2018. Conformément à la recommandation de l'Organisation mondiale de la santé (OMS), fondée sur des données démontrant une efficacité et une durée de protection comparables entre un schéma vaccinal à dose unique et un schéma à doses multiples, le pays est passé à un schéma à dose unique en 2024 et a mené une campagne de vaccination multi-âges (CMA) ciblant les filles âgées de 9 à 14 ans. Cette note résume les conclusions d'une étude menée par PATH en collaboration avec le ministère fédéral de la Santé sur le coût et le contexte opérationnel de l'administration du vaccin contre le HPV pendant la campagne CMA.